New Lung Cancer Data May Offer Reprieve for Peregrine's Bavituximab

Peregrine Pharmaceuticals Inc. is gearing up for a Phase III pivotal study of its bavituximab in second-line non-small cell lung cancer of at the end of 2013, after concluding the drug showed an overall...
Source: OncologySTAT Latest News - Category: Cancer & Oncology Source Type: news